Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA places M-Vax and O-Vax on clinical hold

March 28, 2001

Multiple-cytokine fusion proteins prepared at Lexigen for use in cancer

March 23, 2001

ProstaRex shows broad T-cell response in preclinical prostate cancer studies

March 15, 2001

Cell Genesys initiates phase I/II trial of GVAX cancer vaccine for multiple myeloma

March 8, 2001

AltaRex's OvaRex shows efficacy and safety in phase II trial

March 7, 2001

NeoPharm and NCI expand collaboration for anticancer agent

March 6, 2001

NeoPharm's CRADA agreement for IL-13 receptor research extended

March 1, 2001

Positive quality-of-life and survival results reported for Maxim's Ceplene

March 1, 2001

FDA requests further information for Campath BLA

Feb. 23, 2001

Vical broadens clinical development of Allovectin-7

Feb. 22, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...